Neumora Therapeutics is trading 5.39% higher at $0.45 after hours, with no clear company-specific catalyst for the move. - Shares gained 20.45% in the regular session on October 15; biotech-sector strength may have contributed to that rally. - A separate October 15 report covered Johnson & Johnson’s halted depression-drug development and an analyst downgrade of Neumora, but did not link either to the after-hours rise. - Neumora’s press-release page showed no October 15 announcement.